Bayer is taking collaboration with health care start-ups to the next level

BayerAs a pioneer when it comes to collaborating with digital health start-ups, Bayer is now taking the next step. Instead of one-off startup programs, it is now focusing on collaborating in specific digital health focus areas, e.g. digital therapeutics, AI for drug discovery, and patient engagement platforms to name a few. To do this, Bayer is combining the G4A programs and concentrating on longer-term collaborations and investments. "The digital health ecosystem has matured over the years and there are some very well developed start-ups across the value chain. We wanted to simplify the process for entrepreneurs to work with Bayer and scale innovative solutions together, faster. That's why it's time to take the way we collaborate to the next level," says Eugene Borukhovich, Global Head of Digital Health at Bayer.

The three existing programs (Accelerator, Dealmaker and Generator) are being combined to form G4A Partnerships, a joint initiative aimed at start-ups in the health care sector at various stages of development. Specific business challenges will be defined for which the start-ups can put forward their proposed solutions. The most suitable approaches will then be developed further in collaborative teams with Bayer. The cooperation will be underpinned by a letter of intent. Not only will the start-ups be given one-time initial funding (EUR 50,000 to EUR 100,000), they will also receive additional payments when jointly defined milestones are reached. The first business challenges will be announced at the beginning of April.

"For us, it's all about developing new health solutions that can change the experience of health," says Dr. Zsuzsanna Varga who's heading G4A Partnerships. "We're convinced that long-term collaborations with digital health companies sharing the same passion and vision are the best way to achieve this."

About G4A

Bayer is combining the Group's digital health initiatives under the name G4A (formerly Grants4Apps). In addition to identifying new technologies, business models and market trends, these initiatives also involve collaborating with start-ups. Since its launch in 2013, Bayer has supported over 149 digital health companies. This has resulted in 29 direct collaborations with companies such as Agamon, KinAptic,Turbine, and xbird. Bayer now operates G4A in 12 countries, developing and promoting collaborative health care projects around the world. G4A.Health

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

ACE2 protein protects against severe COVID-19

Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stron...

Neutralizing antibodies protect against severe COV…

Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular...

How SARS-CoV-2 interacts with cells

SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the mo...

Valneva initiates Phase 1/2 clinical study of inac…

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for it...

Vir Biotechnology and GSK announce start of NIH-sp…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Ins...

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

Pfizer and BioNTech receive authorization in the E…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...